State of Michigan Retirement System Sells 9,900 Shares of Eli Lilly and Company $LLY

Key Points

• State of Michigan Retirement System trimmed its stake in Eli Lilly by 3.7%, selling 9,900 shares and now holds 256,704 shares worth about $275.9 million, representing 1.3% of the fund's portfolio and its 13th-largest holding.
• Eli Lilly reported a strong Q1 beat — revenue $19.8B (+55.5% YoY) and EPS $8.55 — and raised FY2026 guidance, with growth driven largely by GLP‑1 medicines (Mounjaro, Zepbound) and early uptake of the oral GLP‑1 Foundayo.
• Risks remain from pricing pressure and competition/generic risk that could erode margins, though an FDA proposal to restrict compounding of tirzepatide/semaglutide may help protect branded sales.

State of Michigan Retirement System lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 256,704 shares of the company's stock after selling 9,900 shares during the quarter. Eli Lilly and Company comprises 1.3% of State of Michigan Retirement System's investment portfolio, making the stock its 13th biggest holding. State of Michigan Retirement System's holdings in Eli Lilly and Company were worth $275,875,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of LLY. Exencial Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock worth $13,283,000 after buying an additional 11,396 shares during the last quarter. Rede Wealth LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $487,000. Cidel Asset Management Inc. grew its stake in shares of Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after buying an additional 5,591 shares during the last quarter. Spire Wealth Management grew its stake in shares of Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after buying an additional 592 shares during the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after buying an additional 8,659 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Earnings beat and guidance raise — Lilly reported Q1 revenue of $19.8B (up ~56% YoY) and non‑GAAP EPS that topped estimates; management raised full‑year 2026 revenue and EPS guidance. Lilly Q1 press release
• Positive Sentiment: GLP-1 sales are the growth engine — Mounjaro and Zepbound volumes drove huge top‑line growth and analysts/Jim Cramer highlighted the large addressable weight‑loss market as a multi‑year tailwind. GLP-1 Sales Continue to Lift Eli Lilly
• Positive Sentiment: Regulatory move could limit compounded competitors — the FDA proposed excluding active ingredients in tirzepatide/semaglutide from the 503B bulks list, which would curb large‑scale compounding of cheaper alternatives and support branded sales. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Foundayo pill early uptake — management said more than 20,000 people have started the newly launched oral GLP‑1 pill, supporting upside potential for incremental sales beyond injections. More than 20,000 people are taking Eli Lilly's weight loss pill
• Neutral Sentiment: Pipeline and tech partnerships — Lilly signed a multi‑year ~$2.25B AI/genetics deal to advance recombinase-based gene editing, which is strategic for long‑term growth but not immediately revenue‑generating. Eli Lilly Signs Up To $2.25 Billion AI Gene Editing Deal
• Neutral Sentiment: Full earnings detail available — the Q1 earnings call transcript and slides give color on volume vs. price, channel mix and Foundayo expectations for investors who want to dig into the drivers. Eli Lilly Q1 2026 Earnings Call Transcript
• Negative Sentiment: Pricing pressure and lower realized prices — management noted strong volume but lower realized prices for GLP‑1s partially offset revenue growth; sustained price erosion would limit margin upside. FT: Lilly profits more than double as weight-loss drug sales soar
• Negative Sentiment: Competition and generics risk — approvals of generic GLP‑1s abroad and mixed early social‑data on Foundayo vs. peers create execution and share‑loss risk that investors should monitor. LLY falls as Canada approves generic weight-loss drugs

Eli Lilly and Company Stock Performance

Shares of LLY opened at $937.04 on Friday. The business's fifty day simple moving average is $947.05 and its two-hundred day simple moving average is $984.98. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a market cap of $885.33 billion, a price-to-earnings ratio of 40.83, a P/E/G ratio of 1.00 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the business posted $3.34 EPS. The company's revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Freedom Capital upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 10th. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a research note on Tuesday, February 10th. Berenberg Bank upped their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a research note on Thursday, February 19th. Finally, The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,216.52.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.